Valo Health Acquires TARA Biosystems Creating First of its Kind Vertically Integrated Cardiovascular Platform
Combined Company to Spearhead Transformation of Cardiovascular Disease Drug Discovery and Development
Valo Health, LLC (“Valo”), announced the acquisition of TARA Biosystems, Inc. (“TARA”), a New York City-based cardiovascular disease biotechnology company, creating the first of its kind vertically integrated cardiovascular drug discovery and development platform. The combination of TARA’s proprietary human three-dimensional tissue engineering and cardiac disease modeling capabilities with Valo’s Opal Computational Platform positions Valo to transform cardiovascular disease drug discovery and development.
Latest Aithority Insights : MATRIXX Software and CompaxDigital Join Forces to Drive New Revenue Growth for Emerging 5G Services
“This acquisition builds on Valo’s unyielding commitment to identify new treatments for cardiovascular disease, creating a best-in-class end-to-end drug discovery and development platform aimed at accelerating the delivery of lifesaving drugs to the millions of patients suffering from cardiovascular diseases,” said David Berry, founder and CEO of Valo.
“TARA’s proprietary human cardiac disease platform enables Valo to advance the discovery of new medicines for cardiovascular disease, ushering in a new era for patients,” said Misti Ushio, founder and CEO of TARA. “TARA joining the Valo family is a natural extension of our pre-existing business relationship and is a unique fit given our shared vision of leveraging machine learning and human-centric data to transform the treatment of cardiovascular diseases.”
Browse The Complete News About Aithority: Comau Introduces Its N-220-2.7 New Generation Robot To Unlock Higher Performance And Cost-effective…
The acquisition of TARA builds on Valo’s extensive cardiovascular platform which already includes deep clinical human cardiovascular disease data giving the company a unique proprietary edge in cardiovascular drug discovery and development. TARA’s state-of-the-art in vitro human cardiac disease models combined with Valo’s artificial intelligence-driven Opal platform – which is built on high-fidelity patient data – creates a vertically integrated platform and a world-class cardiovascular disease franchise.
“There is a significant unmet need in identifying treatments for cardiovascular disease. I believe that the combination of TARA’s in vitro human cardiac model capabilities and Valo’s computational platform will advance the evolution of new cardiovascular disease medicines, and provide hope to countless cardiomyopathy patients,” said Leslie Leinwand, cofounder of Myokardia and current Howard Hughes Professor at the University of Colorado and TARA Scientific Advisor.
Read More About Aithority News : Oriient Announces New Partnership with Google Cloud to Bring Cutting-Edge Micro-Location Services to…
[To share your insights with us, please write to email@example.com]